Tuesday, October 29, 2013
• Clovis Oncology Inc., of Boulder, Colo., reported interim findings from the Phase I dose-escalation portion of its ongoing Phase I/II study of CO-1686, an oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor (EGFR), for the treatment of non-small-cell lung cancer (NSCLC) in patients with initial activating EGFR mutations and the dominant resistance mutation T790M.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.